Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| oxytocin | Experimental | A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril. |
|
| vasopressin | Experimental | A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril. |
|
| placebo | Placebo Comparator | A single dose of placebo will be administered with 3 puffs of treatment to each nostril. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intranasal Oxytocin (IN-OXT) | Drug | Subject assigned to receive intranasal administration of oxytocin (24 IU). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Resting-state EEG | Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index. | 35-50 minutes after treatment administration. |
| Behavioral indices in the tasks | Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious). | 50-90 minutes after treatment administration. |
| Task-based EEG | EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses. | 50-90 minutes after treatment administration. |
| Measure | Description | Time Frame |
|---|---|---|
| SCR in anxiety induction | Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions. | 70-90 minutes after treatment administration. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shuxia Yao, Dr | University of Electronic Science and Technology of China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Electronic Science and Technology of China | Chengdu | Chengdu | 611731 | China | ||
| University of Electronic Science and Technology of China (UESTC) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003919 | Diabetes Insipidus |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intranasal Vasopressin (AVP) | Drug | Subjects assigned to receive intranasal administration of vasopressin (20 IU). |
|
| Intranasal Placebo | Drug | Subjects assigned to receive intranasal administration of placebo. |
|
| Chengdu |
| Sichuan |
| 611731 |
| China |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |